Improved Migraine Treatment Outcomes with Rizatriptan 10 mg Compared to Non-triptan Treatment. I-MAX Migraine Disability Assessment Program, Spain

By Torrecilla M.   Caloto M.T.   Nocea G.   Gerth W.C.  

Headache Care, Vol. 1, Iss. 1, 2004-03 ,pp. : 50-54

Informa Healthcare

Access to resources Recommend Favorite

Usefulness of a Disability Diary to Facilitate Communication Between Migraine Patients and Primary Care Physicians in Assessing Symptoms, Migraine-related Disability and Medication Effectiveness. The I-MAX Migraine Disability Assessment Program, Spain

By Baos V.   Torrecilla M.   Serrano A.   Caloto M.T.   Nocea G.   Gerth W.C.  

Headache Care, Vol. 1, Iss. 1, 2004-03 ,pp. : 33-38

Informa Healthcare

Access to resources Recommend Favorite

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine

By Dahlöf Carl   Jones Martin   Davis Kim   Loftus Jane   Salonen Reijo  

The Journal of Headache and Pain, Vol. 5, Iss. 2, 2004-08 ,pp. : 115-122

Springer Publishing Company

Access to resources Recommend Favorite

acute migraine: which triptan?

By  

PRACTICAL NEUROLOGY, Vol. 4, Iss. 1, 2004-02 ,pp. : 6-19

John Wiley & Sons Inc

Access to resources Recommend Favorite

A longitudinal evaluation of changes in disability and quality of life in a sample of women with migraine

By Raggi Alberto   Leonardi Matilde   Giovannetti Ambra   Curone Marcella   Bussone Gennaro   D’Amico Domenico  

Neurological Sciences, Vol. 32, Iss. 1, 2011-05 ,pp. : 189-191

Springer Publishing Company

Access to resources Recommend Favorite